We are removing Hologic from Investing Ideas today.
According to Hedgeye's Healthcare team:
While 3D adoption continues to track closely with our long-term model, the 3D Tomo Tracker showed a deceleration in new placements in February from the prior month. Given the recent guidance raise we need to see a pickup in March placements for them to hit consensus expectations for the Breast Health segment.
In addition, as CEO Keith McCullough notes, equity market beta is at all time highs.
According to McCullough: "We can always come back to this name – right now we are booking the big win."
Hologic is up over +23% since it was added on 1/2/15 compared to around +3% for the S&P 500.
Click to enlarge.
